Eric Ojerholm
Papers
2
Total Citations
171
H-Index
2
About
Eric Ojerholm is a radiation oncologist whose research focuses on de-intensifying treatment for human papillomavirus (HPV)-related oropharyngeal cancer, aiming to reduce long-term toxicity without compromising oncologic outcomes. His most impactful work, the AVOID phase 2 trial (167 citations), demonstrated that omitting radiation to the resected primary tumor bed after transoral robotic surgery is feasible and safe for select patients, challenging conventional treatment paradigms. This study has influenced clinical practice by identifying candidates for less aggressive radiotherapy, thereby minimizing swallowing dysfunction and xerostomia. Ojerholm’s contributions extend to refining risk-adapted strategies in head and neck cancer, where his earlier commentary (2016) critically evaluated the benefits of omitting primary site radiation, sparking dialogue on balancing efficacy with quality of life. His research, grounded in prospective clinical trials, has shaped modern de-escalation protocols and earned recognition within the radiation oncology community. For students and researchers, Ojerholm’s work exemplifies how thoughtful trial design can transform care for HPV-positive patients, offering a roadmap for future investigations into personalized, toxicity-sparing therapies.
Research Focus
Key Achievements
Top Papers
- 1
- 2